3 registrations that name vitamin K2 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
All 3 registrations
RecruitingNCT05943457
Vitamin K2 Supplementation in Adult Episodic Migraine
No phase
Sola Aoun Bahous, M.D. Ph.D.
About 160 people
Started Mar 6, 2024
In plain words A study of vitamin K2 in people 18 and older, run by Sola Aoun Bahous, M.D. Ph.D.. It plans to enroll about 160 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Migraine Headache; Arterial Stiffness; Vitamin K Deficiency.
Adults aged 18 years or above
History of episodic migraine with or without aura since > 12 months according to the ICHD-3 criteria.
Migraine frequency from 4-14 days per month over the 3 months prior to screening.
Migraine frequency from 4-14 days per month during the baseline period of assessment.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Vitamin K2 or menaquinone-7; Placebo
Registered summary
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). The full summary is on the listing.
Where, as registered
No US site; Lebanon (1).
RecruitingNCT06867952
A Pilot Study of Vitamin K2 (Menaquinone-7, Soloways ™) in Patients With Osteopenia/Osteoporosis Carrying a VDR Gene Variant
No phase
S.LAB (SOLOWAYS)
About 40 people
Started May 3, 2024
In plain words A study of vitamin K2 in people 40 to 75, run by S.LAB (SOLOWAYS). It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 75. Conditions: Osteoporosis; Osteopenia.
Adults aged 40-75 years with a confirmed DXA-based diagnosis of osteopenia or osteoporosis (T-score ≤ -1.0).
Stable dietary habits and willingness to maintain current exercise regimen throughout the study.
Willingness to undergo genotyping for the VDR variant. For the VDR Variant Cohort: confirmed homozygous "unfavorable" variant (e.g., BsmI or ApaI).
For the Non-Variant Cohort: confirmed absence of the "unfavorable" allele (wild-type).
The exclusion criteria are on the listing.
What it tests, as registered
Vitamin K2 plus vitamin D3; Vitamin K2 plus vitamin D3
Registered summary
This pilot, genotype-stratified clinical trial aims to evaluate the safety and preliminary efficacy of vitamin K2 (menaquinone-7, MK-7) supplementation in patients with low bone mineral density (osteopenia or osteoporosis) who carry a specific "unfavorable" variant in the vitamin D receptor (VDR) gene (e.g., BsmI or ApaI polymorphisms). The trial will compare improvements in bone health and related biomarkers between two cohorts: (1) homozygous carriers of the VDR variant and (2) non-variant carriers (wild-type). The full summary is on the listing.
Where, as registered
No US site; Russia (1).
RecruitingNCT06707909
The Local Effect of Vitamin K2 on Bone Remodeling in Socket Preservation
Phase 4
Cairo University
About 20 people
Starts Feb 15, 2025 (estimated)
In plain words A Phase 4 study of vitamin K2 in people 18 to 80, run by Cairo University. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80; healthy volunteers accepted. Conditions: Socket Preservation.
Patients requiring extraction of mandibular single-rooted teeth.
The exclusion criteria are on the listing.
What it tests, as registered
Menaquinone
Registered summary
This study is a randomized controlled trial comparing the effects of socket grafting with crushed vitamin K2 (menaquinone)capsules versus no grafting on bone density and socket dimensions following tooth extraction. Patients are randomly assigned to one of two groups: Study Group (Group I): Patients receive socket grafting with crushed vitamin K2 (menaquinone) capsules. The socket is covered with an absorbent sponge, and non-resorbable sutures are placed to stabilize the graft material and achieve soft tissue stability. The full summary is on the listing.